Korpal-Szczyrska Maria, Dorant Bohdana, Kamińska Halina, Birkholz Dorota, Niedźwiecki Maciej
Klinika Pediatrii, Hematologii, Onkologii i Endokrynologii AM w Gdańsku, Gdańsk.
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2006;12(1):31-4.
Growth hormone (GH) therapy has been used for children with pituitary GH deficiency. It resulted in improving their height velocity and achieving an adult height in the normal range for the general population.
To evaluate the final height in childhood-onset growth hormone deficiency patients who had already completed treatment and were still GH deficient in adult life.
21 children (12 boys and 9 girls) diagnosed as GH deficiency and treated with growth hormone to final height at doses of 0.17 mg/kg/week (0.5 IU/kg/week) subcutaneously for 7 days. There were 7 patients with isolated GHD and 14 with multiple pituitary hormone deficiencies.
At the diagnosis peak serum GH concentrations were 2.8+/-2.8 mU/l in insulin tolerance test and 3.3+/-2.2 mU/l in clonidine test. Reconfirmation of the GH deficiency diagnosis after growth hormone treatment revealed a peak serum GH 1.77+/-1.2 mU/l in insulin tolerance test. Mean chronological age of the patients at the beginning of treatment was 10.29+/-3.57 years and was significantly higher in boys. Patients had completed a course of treatment in the chronological age of 17.85+/-1.97 years. Children began treatment with mean bone age 7.24+/-3.57 years and ended with 15+/-0.97 years. After the treatment a significant improvement in height was shown. Height SDS at the beginning of the treatment was -4.03+/-0.91 and -0.69+/-1.01 after the treatment. There was no difference between final height and target height (-0.54+/-0.93 SDS) in our patients.
Children with pituitary growth hormone deficiency who were treated with growth hormone replacement achieve a final height in the normal range for the general population and their target height.
生长激素（GH）疗法已用于治疗垂体性生长激素缺乏症儿童。该疗法可提高他们的身高增长速度，并使成年身高达到普通人群的正常范围。
评估已完成治疗且成年后仍存在生长激素缺乏的儿童期起病的生长激素缺乏症患者的最终身高。
21名被诊断为生长激素缺乏症的儿童（12名男孩和9名女孩）接受生长激素治疗直至最终身高，皮下注射剂量为0.17mg/kg/周（0.5IU/kg/周），共7天。其中7例为单纯生长激素缺乏症患者，14例为多种垂体激素缺乏症患者。
诊断时，胰岛素耐量试验中血清生长激素峰值浓度为2.8±2.8mU/L，可乐定试验中为3.3±2.2mU/L。生长激素治疗后再次确认生长激素缺乏症诊断，胰岛素耐量试验中血清生长激素峰值为1.77±1.2mU/L。患者开始治疗时的实际平均年龄为10.29±3.57岁，男孩的年龄显著更高。患者在实际年龄17.85±1.97岁时完成了一个疗程的治疗。儿童开始治疗时平均骨龄为7.24±3.57岁，结束时为15±0.97岁。治疗后身高有显著改善。治疗开始时身高标准差分数为-4.03±0.91，治疗后为-0.69±1.01。我们的患者最终身高与靶身高之间无差异（-0.54±0.93标准差分数）。
接受生长激素替代治疗的垂体性生长激素缺乏症儿童的最终身高达到普通人群的正常范围及其靶身高。
